DARE (Daré Bioscience, Inc.) Gross Profit Margin

Official company branding of Dare Bioscience Inc. (DARE)

Dare Bioscience, Inc. (DARE) develops biopharmaceuticals for women within a stable US legal framework devoid of trade barriers. This gross margin chart demonstrates operational efficiency, with the current figure standing at -135.80. Profit growth is driven by the market launch of XACIATO and new contraceptives. Simultaneously, the company adheres to WHO standards regarding research ethics and the safe disposal of chemical reagents.

DARE (darebioscience.com) Gross Margin history from 07/04/2022 to 11/19/2026

Analytical breakdowns and data insights for company Dare Bioscience (DARE)

Basic company analysis:DARE - Daré Bioscience
Mass-produced product of Daré Bioscience

Gross margin measures the efficiency of direct production, reflecting the profit share after deducting the cost of goods sold, which allows for an assessment of the business's operational resilience and pricing power. For Dare Bioscience, Inc. (DARE), whose women's health developments rely on complex clinical trials, the gross margin ratio demonstrates the ability to monetize innovative therapeutic systems, separating real growth from temporary expenditures.